Parenteral vs. oral sumatriptan and naratriptan: Plasma levels and efficacy in migraine. A comment

Journal of Headache and Pain

Volumn 8, Issue 5, 2007, Pages 273-276

  Tfelt Hansen, Peer ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Migraine; Naratriptan; Oral administration; Subcutaneous administration; Sumatriptan

Indexed keywords

NARATRIPTAN; PLACEBO; SUMATRIPTAN; ZOLMITRIPTAN;

CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; HUMAN; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; HUMANS; INFUSIONS, PARENTERAL; INJECTIONS, SUBCUTANEOUS; MIGRAINE DISORDERS; PIPERIDINES; SEROTONIN AGONISTS; SUMATRIPTAN; TIME FACTORS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 36749023520     PISSN: 11292369     EISSN: 11292377     Source Type: Journal    
DOI: 10.1007/s10194-007-0411-x     Document Type: Review

References (23)

1. Thomsen LL, Dixon R, Lassen LH et al (1996) 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: A comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia 16:270-275
2. Sternieri E, Pinetti D, Coccia CP et al (2005) Pharmacokinetics of sumatriptan in non-responders and in adverse drug reaction reporting migraine patients. J Headache Pain 6:319-321
3. Visser WH, Burggraaf and adverse J, Muller LM et al (1996) Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Clin Pharmacol Ther 60:452-460
4. Saxena PR, Tfelt-Hansen P (2006) Triptans, 5HT1B/1D agonists in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches. 3rd Ed. Philadelphia: Lippincott Williams & Wilkins 469-503
5. Tfelt-Hansen P, De Vries P, Saxena PR (2000) Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60:1259-1287
6. Tfelt-Hansen P (1993) Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials. Cephalalgia 13:238-244
7. Humphrey PP (2007) The discovery of a new drug class for the acute treatment of migraine. Headache 47(Suppl 1):S10-S19
8. Lacey LF, Hussey EK, Fowler PA (1995) Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 47:543-548
9. Dahlöf C, Hogenhuis L, Olesen J et al (1998) Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: A dose-ranging study. Eur J Neurol 5:469-477
10. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT1B/!D agonists) in acute migraine: A meta-analysis of 53 trials. Lancet 358:1668-1675
11. International Headache Society Clinical Trial Subcommittee (2000) Guidelines for controlled trials of drugs in migraine. Second edition. Cephalalgia 20:765-786
12. Oral Sumatriptan Dose Defining Study Group (1991) Sumatriptan - an oral dose defining study. Eur Neurol 31:300-305
13. Mathew NT, Dexter J, Couch J et al (1992) Dose ranging efficacy of safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Study Group. Arch Neurol 49:1271-1276
14. Visser WH, Ferrari MD, Bayliss EM et al (1992) Treatment of migraine attacks with subcutaneous sumatriptan: First placebo-controlled study. The Subcutaneous Sumatriptan International Study Group. Cephalalgia 12:308-313
15. Havanka H, Dahlöf C, Pop H et al (2000) Efficacy of naratriptan in the acute treatment of migraine: A dose-ranging study. Naratriptan S2BW2004 Study Group. Clin Ther 22:970-980
16. Mathew NT, Asgharenjad M, Peykamian M, Laurenza A (1997) Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group. Neurology 49:485-490
17. Klassen A, Elkind A, Asgharnejad M et al (1997) Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. The Naratriptan S2WA3001 Study Group. Headache 37:640-645
18. Tfelt-Hansen P. Maximum effect of triptans in migraine? A comment. Cephalalgia, in press
19. Volans GN (1974) Absorption of effervescent aspirin during migraine. BMJ 4:265-269
20. Tfelt-Hansen P, Young WB, Silberstein SD (2006) Antiemetics, prokinetics, neuroleptic and miscellaneous drugs in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches. 3rd Eds. Philadelphia: Lippincott Williams & Wilkins 505-513
21. Jhee SS, Shiovitz T, Crawford AW, Cutler NR (2001) Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: A comparative review. Clin Pharmacokinet 40:189-205
22. Sumatriptan Cluster Headache Study Group (1991) Treatment for acute cluster headache with sumatriptan. N Eng J Med 325:322-326
23. Connor HE, Feniuk W, Beattie DT et al (1997) Naratriptan: Biological profile in animal models relevant to migraine. Cephalalgia 17:145-152